- Home
- CPBI vs ANVS Comparison
CPBI vs ANVS Comparison
Compare CPBI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | ANVS |
|---|---|---|
| Founded | 2023 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.5M | 69.1M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CPBI | ANVS |
|---|---|---|
| Price | $19.62 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 2.9K | ★ 954.8K |
| Earning Date | 06-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.38 | ★ 39.39 |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.85 | $1.54 |
| 52 Week High | $21.83 | $5.50 |
Technical Indicators
Market Signals| Indicator | CPBI | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 64.87 | 42.09 |
| Support Level | $17.03 | $1.66 |
| Resistance Level | N/A | $2.57 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 30.46 | 18.10 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.